956100-63-3

Usage

Uses

Used in Pharmaceutical Research and Development:
8-Bromo-2-chloroquinazoline is utilized as a building block in the synthesis of biologically active compounds, contributing to the development of new medications due to its unique structural and chemical properties.
Used in Chemical Research:
8-BROMO-2-CHLOROQUINAZOLINE serves as a valuable starting material for chemical research, allowing scientists to explore its reactivity and potential in creating novel chemical entities.
Used in Agrochemical Development:
8-Bromo-2-chloroquinazoline may be employed in the development of agrochemicals, where its specific chemical properties could be leveraged to enhance crop protection or yield.
Used in Dye Production:
Its potential use in the creation of dyes for various industries, including textiles and printing, is another application, capitalizing on its chemical structure to produce specific colorants.
Used in Industrial Product Development:
8-BROMO-2-CHLOROQUINAZOLINE's properties make it an interesting candidate for further exploration in the development of other industrial products, where its unique characteristics could be applied to improve existing technologies or create new ones.

InChI:InChI=1/C8H4BrClN2/c9-6-3-1-2-5-4-11-8(10)12-7(5)6/h1-4H

Upstream product

• 956100-62-2 8-bromo-2-chloroquinazolin-4-amine 
• 331647-05-3 8-bromo-2,4-dichloroquinazoline 
• 20776-51-6 2-amino-3-bromo benzoic acid 
• 331646-99-2 8-bromoquinazoline-2,4-(1H,3H)-dione 
• 331646-99-2 8-bromoquinazoline-2,4-diol 

Downstream Products

• 1292267-48-1 C₂₈H₂₀FN₇O 
• 1292267-76-5 C₂₁H₁₄BrN₇ 
• 1292267-72-1 C₂₀H₁₈BrN₇O 
• 1292267-38-9 C₂₆H₂₄N₈O 
• 1292267-39-0 C₂₄H₂₃N₉O 
• 1292267-40-3 C₂₇H₂₄FN₇O₂ 
• 1292267-41-4 C₂₃H₂₀N₈OS 
• 1292267-45-8 C₂₆H₂₃N₇O 
• 1292267-46-9 C₂₄H₁₉FN₆O 
• 1292267-47-0 C₂₀H₁₅N₇S 
• 1292267-73-2 C₁₇H₁₃BrN₆ 

Relevant academic research and scientific papers

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS

The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).